The deal provides access to a lucrative respiratory drug market as the company seeks to rebuild its pipeline.
This speculative drug stock is targeting the growing global problem of hospital-based infections.
The stock has had a great run, meeting aggressive targets.
These defensive plays yield up to 8%. And best of all, it's not too late to buy.
Some major branded drugs will lose patent protection, and market share along with it, this year.
The pharmaceutical company's new CEO formerly worked for the Canadian company, long a rumored suitor.
The biotech was rumored to be a takeover target but aims to be a buyer instead.
VIDEO ON MSN MONEY
Copyright © 2014 Microsoft. All rights reserved.
The S&P 500 manages to keep a deathgrip on 2,000, but key areas of the market are already buckling under pressure.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
Six weeks later, most Americans have forgotten about the 2014 tax season -- except those who didn't file by the April 15 deadline.
MUST-SEE ON MSN
A charcuterie master shares his process for cold-smoking meat at home.
- Jetpacks about to go mainstream
- Weird things covered by home insurance
- Bing: 70 percent of adults report 'digital eye strain'